VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES
65.36
13-3月-25 15:00:01
15 分の遅延
株式
-2.24
-3.31%
本日の幅
65.24 - 68.52
ISIN
N/A
ソース
NASDAQ
-
02 5 2023 01:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
25 4 2023 01:00:00 提供 Nasdaq GlobeNewswire
-
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
10 4 2023 01:00:00 提供 Nasdaq GlobeNewswire
-
07 3 2023 01:00:00 提供 Nasdaq GlobeNewswire
-
21 2 2023 01:00:00 提供 Nasdaq GlobeNewswire
-
20 12 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
19 12 2022 15:01:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09 11 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma Announces November 2022 Investor Conference Participation
02 11 2022 02:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
26 10 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
17 10 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
14 10 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
29 8 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma strengthens commercialization leadership team
24 8 2022 01:00:00 提供 Nasdaq GlobeNewswire
-
19 8 2022 01:46:07 提供 Nasdaq GlobeNewswire
-
15 8 2022 15:05:00 提供 Nasdaq GlobeNewswire
-
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
10 8 2022 19:22:20 提供 Nasdaq GlobeNewswire
-
Verona Pharma plc Announces Proposed Underwritten Public Offering
09 8 2022 15:16:44 提供 Nasdaq GlobeNewswire
-
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
09 8 2022 02:01:03 提供 Nasdaq GlobeNewswire
-
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
09 8 2022 01:00:00 提供 Nasdaq GlobeNewswire